newsfilter
← Latest News
GlobeNewswire·

Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results

Positive Phase 3 data from ORIGIN 3 study of atacicept in IgA nephropathy (IgAN) presented at American Society of Nephrology (ASN) Kidney Week and published in the New England Journal of MedicineU.S. Food and Drug